Owner Scorecard


← Japan catalog ← 4502 Manual 4506 → ← 4502 Pharmaceuticals 4506 →

4503 · Astellas Pharma

Pharma Asset-light compounder IFRS
Latest filing: FY2026 annual securities report (有価証券報告書) · EDINET

This is a quantitative scorecard. The numbers below are read directly from Astellas Pharma’s EDINET filing, in yen. The Japanese-language narrative, what the business does, its risks, what changed this year, is not machine-read here, so we do not paraphrase it. Find it on EDINET (code 4503) →

I

The record

What the business has done across the cycle, read straight from the EDINET filing: the multi-year record, and the walk from reported profit to the cash an owner could take out.

The record, 2017–2026

realized figures from each filing · older years to the left
2017’172018’182019’192020’202021’212022’222023’232024’242025’252026’26
Income statement
¥1.31T¥1.30T¥1.31T¥1.30T¥1.25T¥1.30T¥1.52T¥1.60T¥1.91T¥2.14TRevenueRevenue
79%80%82%81%Gross marginGross mgn
38%40%44%40%SG&A / revenueSG&A/rev
13%11%9%8%R&D / revenueR&D/rev
¥15.6B¥213.3B¥243.9B¥244.0B¥136.1B¥155.7B¥133.0B¥25.5B¥41.0B¥382.6BOperating incomeOp. inc.
1.2%16.4%18.7%18.8%10.9%12.0%8.8%1.6%2.1%17.9%Operating marginOp. mgn
¥218.7B¥164.7B¥222.3B¥195.4B¥120.6B¥124.1B¥98.7B¥17.0B¥50.7B¥291.5BNet incomeNet inc.
Cash flow & returns
¥235.6B¥312.6B¥258.6B¥222.0B¥306.8B¥257.4B¥327.8B¥172.5B¥194.5B¥560.2BOperating cash flowOp. cash
¥16.9B¥147.9B¥36.4B¥26.6B¥186.3B¥133.4B¥229.1B¥155.4B¥143.8B¥268.7BWorking capital & otherWC & other
¥25.1B¥25.2B¥41.3B¥31.4B¥30.7B¥36.4B¥38.1B¥37.0B¥57.7BCapexCapex
1.9%1.9%3.2%2.5%2.4%2.4%2.4%1.9%2.7%Capex / revenueCapex/rev
¥287.5B¥233.4B¥180.7B¥275.5B¥226.7B¥291.3B¥134.4B¥157.5B¥502.5BOwner earningsOwner earn.
22.1%17.9%13.9%22.0%17.5%19.2%8.4%8.2%23.5%Owner earnings marginOE mgn
¥287.5B¥233.4B¥180.7B¥275.5B¥226.7B¥291.3B¥134.4B¥157.5B¥502.5BFree cash flowFCF
22.1%17.9%13.9%22.0%17.5%19.2%8.4%8.2%23.5%Free cash flow marginFCF mgn
¥70.1B¥71.7B¥72.1B¥73.6B¥76.3B¥85.6B¥100.9B¥117.6B¥130.3B¥137.5BDividends paidDiv. paid
¥92.2B¥130.7B¥160.4B¥52.9B¥9.2B¥50.7B¥60.6B¥10.7B¥7.0B¥730MBuybacksBuybacks
1%13%14%15%8%9%8%1%2%14%ROICROIC
17%13%18%15%9%8%7%1%3%16%Return on equityROE
12%7%12%9%3%3%−0%−6%−5%8%Retained to equityRetained/eq
Balance sheet
¥96.8B¥331.7B¥311.1B¥320.4B¥326.1B¥316.0B¥376.8B¥335.7B¥188.4B¥281.6BCash & investmentsCash+inv
¥169.6B¥25.3B¥189.8B¥158.6B¥149.8B¥146.2B¥148.7B¥194.7B¥194.4B¥234.1BReceivablesReceiv.
¥97.5B¥54.0B¥55.1B¥49.0B¥45.9B¥28.5B¥50.7B¥61.4B¥75.5B¥70.0BInventoryInvent.
¥267.2B¥79.3B¥244.9B¥207.6B¥195.7B¥174.7B¥199.4B¥256.1B¥269.9B¥304.1BOperating working capitalOper. WC
¥481.0B¥845.6B¥857.2B¥867.5B¥872.6B¥923.4B¥1.05T¥1.19T¥1.20T¥1.42TCurrent assetsCur. assets
¥572.7B¥538.7B¥650.1B¥653.4B¥476.5B¥505.4B¥405.6B¥856.5B¥626.5B¥717.0BCurrent liabilitiesCur. liab.
0.8×1.6×1.3×1.3×1.8×1.8×2.6×1.4×1.9×2.0×Current ratioCurr. ratio
¥213.0B¥225.9B¥278.3B¥284.0B¥303.0B¥328.4B¥418.7B¥415.2B¥441.2BGoodwillGoodwill
¥1.81T¥1.86T¥1.90T¥2.32T¥2.27T¥2.33T¥2.46T¥3.57T¥3.34T¥3.57TTotal assetsAssets
¥379.7B¥367.9B¥445.7B¥288.0B¥317.2B¥224.4B¥125.0B¥920.0B¥831.4B¥566.0BTotal debtDebt
¥282.9B¥36.2B¥134.6B(¥32.4B)(¥8.9B)(¥91.6B)(¥251.8B)¥584.3B¥643.1B¥284.3BNet debt / (cash)Net debt
11.9×119.7×354.0×109.3×64.2×67.3×41.4×3.4×2.9×37.1×Interest coverageInt. cov.
¥1.27T¥1.27T¥1.26T¥1.29T¥1.39T¥1.46T¥1.51T¥1.60T¥1.51T¥1.83TShareholders’ equityEquity
Per share
2.15B2.07B1.98B1.86B1.86B1.84B1.81B1.81B1.81B1.81BShares out (diluted)Shares
¥608.99¥628.53¥659.83¥698.71¥671.14¥706.03¥839.17¥886.17¥1056.73¥1182.12Revenue / shareRev/sh
¥101.54¥79.60¥112.27¥104.96¥64.77¥67.59¥54.55¥9.42¥28.04¥161.10EPS (diluted)EPS
¥138.99¥117.91¥97.07¥147.95¥123.49¥160.98¥74.28¥87.04¥277.66Owner earnings / shareOE/sh
¥138.99¥117.91¥97.07¥147.95¥123.49¥160.98¥74.28¥87.04¥277.66Free cash flow / shareFCF/sh
¥32.57¥34.64¥36.42¥39.53¥40.97¥46.62¥55.77¥64.97¥71.98¥75.98Dividends / shareDiv/sh
¥12.12¥12.72¥22.17¥16.86¥16.74¥20.14¥21.03¥20.45¥31.90Cap. spending / shareCapex/sh
¥590.49¥613.05¥635.61¥692.44¥744.51¥795.44¥833.28¥881.93¥836.21¥1010.71Book value / shareBVPS
Per-share growththe realized rate an owner's share compounded
9-yr5-yr
Revenue / share+7.6%/yr+12.0%/yr
Owner earnings / share+9.0%/yr (8-yr)+13.4%/yr
EPS+5.3%/yr+20.0%/yr
Dividends / share+9.9%/yr+13.1%/yr
Capital spending / share+12.9%/yr (8-yr)+13.6%/yr
Book value / share+6.2%/yr+6.3%/yr

Net income is the accountant's number; owner earnings is the cash an owner could take out. The walk between them, off the cash-flow statement, and whether the gap is widening or holding.

In fiscal 2026 the business turned ¥291.5B of profit into ¥502.5B of owner earnings: more cash than the profit line showed, after the non-cash charges and the capital it put back in.

Reported net income¥291.5B
Owner earnings¥502.5B · 23% of revenue
FY2026FY2025FY2024FY2023FY2022
Reported net income¥291.5B¥50.7B¥17.0B¥98.7B¥124.1B
Working capital & othertiming of cash in and out, other non-cash items+¥268.7B+¥143.8B+¥155.4B+¥229.1B+¥133.4B
Cash from operations¥560.2B¥194.5B¥172.5B¥327.8B¥257.4B
Capital expenditurecash put back in to keep running and to grow−¥57.7B−¥37.0B−¥38.1B−¥36.4B−¥30.7B
Owner earnings¥502.5B¥157.5B¥134.4B¥291.3B¥226.7B
Owner-earnings marginowner earnings ÷ revenue23%8%8%19%17%

Owner earnings is the cash an owner could pull out without starving the business: operating cash less the capital it must spend to hold its position .

Maintenance capex is estimated as depreciation where a growing business invests above it; free cash flow is the figure the scorecard's free-cash margin reads.

II

Quality & stewardship

Returns, the balance sheet, and stewardship. The same checks the US pages run, in yen.

Owner’s Scorecard

FY2026 Annual securities report · source on EDINET →

Will it survive?

  • Comfortable
    Operating income ¥382.6B ÷ interest expense ¥10.3B
    What this means

    Operating profit covers interest with the kind of margin Graham wanted for a defensive holding. Necessary, not sufficient, it says solvent, not cheap.

  • How heavy is the debt, net of cash? ¥284.3B · 0.7× operating profit
    Modest net debt
    Cash ¥281.6B − debt ¥566.0B
    What this means

    Netting ¥281.6B of cash and short-term investments against ¥566.0B of debt leaves ¥284.3B owed, about 0.7× a year's operating profit (1.5× on the gross debt, before the cash). Net debt is the leverage figure that matters: the cash is already set against the debt. Strategic or illiquid investments aren't counted here.

  • Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Is it a good business?

  • Solid through the cycle
    10-yr median, range 1%–15%; 14% latest = NOPAT ¥302.3B ÷ invested capital ¥2.11T
    Industry peers: median 21%
    What this means

    The rate the business earns on the money tied up in it, Buffett's north star, because over time a stock tracks the ROIC beneath it. Above ~15% sustained hints at a moat; a return below the cost of capital (~8%) erodes value as a business grows rather than building it — the test Buffett weighs most. The headline is the median of the last 10 years (it ran 14% most recently), so one peak or trough year doesn't set the verdict. Asset-light businesses (R&D expensed, little capital) read artificially high, pair this with Owner Earnings.

  • High through the cycle
    9-yr median margin, range 8%–23%; latest ¥502.5B = operating cash ¥560.2B − maintenance capex ¥57.7B
    Industry peers: median 36%
    What this means

    What an owner could take out without starving the business: operating cash less the maintenance capital it must spend to hold its position — Buffett's owner earnings. That's 23% of revenue this year, a 18% median across 9 years.

  • Cash-backed
    Cash from ops ¥560.2B ÷ net income ¥291.5B
    What this means

    How much of reported profit showed up as operating cash. Above 1× is reassuring; well below suggests earnings lean on accruals. One year is noisy, growth and working-capital swings distort it, and this is operating cash, not free cash. Watch the multi-year trend.

How is the cash used?

  • Reinvests most of it
    Dividends + buybacks ¥138.2B ÷ Owner Earnings ¥502.5B
    What this means

    Of ¥502.5B Owner Earnings, ¥138.2B (28%) went back to shareholders, ¥137.5B dividends, ¥730M buybacks. Returning most of it is the mark of a mature business with little left to reinvest at a high return; reinvesting most could mean a long runway, or empire-building. The split doesn't say which; the return earned on it (see ROIC) does.

  • Investing or harvesting?
    Not enough data
    What this means

    The filing data didn't include the inputs for this check.

Durability & moat, 2017–2026

Whether the record’s returns held, and what the capital reinvested earned.

  • Profitable years 10 of 10
    What this means

    Never lost money over the record, the earnings stability Graham insisted on.

  • Return on capital ≥ 15% 1 of 10 yrs
    What this means

    A moat shows up as a high return on invested capital that holds year after year, not one good vintage.

  • Operating margin 12% → 7% (3-yr avg ends)
    What this means

    The recent-years average (7%) sits below the early years (12%), but the latest year (18%) is back near the early level: a cyclical trough dragging the window down, not a one-way slide. The through-cycle median is 11% — read it across the cycle, not on the dip.

  • Reinvestment, incremental ROIC −1%
    What this means

    Reinvested capital came back at a negative incremental return over this window — the invested base grew while operating profit did not. The filings show where it went.

  • Owner earnings growth +3%/yr
    What this means

    Owner earnings grew about 3% a year over the record.

  • Worst year 2017 · 1.2% op. margin
    What this means

    Stayed profitable even in its hardest year, the resilience that survives recessions.

  • Share count −1.9%/yr
    What this means

    The share count is shrinking, buybacks are quietly growing your slice of the business.

  • Dividend record rising
    What this means

    Paid and raised the dividend across the record, the continuity Graham prized.

All figures as filed; the source filing is linked above.

How the cash was used, 2018–2026

Over the record, the business generated ¥2.61T of operating cash; how management split it reads as a balanced allocator, splitting cash between the business, owners, and the balance sheet.

  • Reinvested¥322.9B · 12%
  • Dividends¥865.5B · 33%
  • Buybacks¥482.9B · 18%
  • Retained (debt / cash)¥941.2B · 36%
  • Returned to owners¥1.35T

    59% of the owner earnings the business produced over the span, ¥865.5B as dividends and ¥482.9B as buybacks.

  • Average price paid for buybacks

    Buybacks ran ¥482.9B over the span, but the filings don't tag the share count needed to deduce the average price paid.

  • Net change in share count−12.5%

    The diluted count fell from 2069M to 1810M, so the buybacks outran the stock issued to staff.

  • Dividend record¥75.98/sh

    Paid in 9 of the years on record, the per-share dividend growing about 10% a year. It was never cut over the span.

Buybacks are gross of stock issued to staff; the share-count line above is the net of that, the figure that decides whether owners gained. The average price paid blends a year of purchases (and any accelerated repurchase), so it is close, not exact. The record of where the cash went and on what terms.

Inverting the record

Invert: instead of why Astellas Pharma is a good business, the question is what would make owning it a mistake, and whether those marks are in the record. Disconfirming tests across 2017–2026.

1 of the 5 tests turned up something to look into; the other 4 came back clean.

  • Look hereDid debt outgrow the business?¥379.7B → ¥566.0B

    Debt rose from ¥379.7B to ¥566.0B while owner earnings went from about ¥233.9B to ¥264.8B — about 1.6 years of owner earnings in debt then, about 2.1 now: measured against what the business earns, the balance sheet carries more debt than it did. Debt raised for buybacks or deals rather than growth is the kind that bites in a downturn.

And these came back clean
  • Is it less profitable than it was?
  • Did the share count rise anyway?
  • Did reported profit become cash?
  • Did receivables and inventory outpace sales?

Each test is read from the filings and is noisy alone; a flag can mark a cyclical trough or a year of heavy investment as easily as a problem. The filing says which.

III

The price

What a price would have to assume, set against the record above.

What the price implies

reverse-DCF

Type today's close and see the owner-earnings growth you'd have to believe to justify it, beside what Astellas Pharma has delivered.

Astellas Pharma’s latest year runs above its own through-cycle margin — the reported figure may flatter a peak. So the tool opens on the through-cycle base, Graham’s averaging cutting both ways; clear the toggle below to read the latest year exactly as reported.

¥

Through the cycle, Astellas Pharma earns about ¥382.3B on its 17.9% median owner-earnings margin. This year’s 23.5% margin runs above that; the reported figure may flatter a peak you'd be paying on. Normalize, below, values the price on that through-cycle figure rather than the latest year. It comes pre-checked here for that reason, the same rule that already normalizes a trough; clear it to price the year as filed.

Base

The assumptions

9.0% = the 4.55% 10-year Treasury (Jul 15, 2026) + 4.45 points of equity premium. The rate you require is yours to set.

Enter a price above to run it.

Implied by the price
Owner-earnings growth · ’22→’26+6%/yr
Owner-earnings growth · ’18→’26+3%/yr
Owner-earnings yield
P/E (3-yr earnings ’24–’26)
P/B
Graham’s price gate

Graham capped the multiple at 15×; Buffett and Munger let that rule go: a wonderful business can deserve 50× if the thesis holds. The gate marks the bargain-hunter's floor.

Against a high-grade bond: Graham’s yardstick bond yield%

Prefilled with the 10-year Treasury (4.55%, as of Jul 15, 2026). Edit it for today’s exact figure, or a AAA corporate yield.

Graham measured a stock against the bond you could own instead, the heart of his margin of safety. Enter a price above to weigh the owner-earnings yield against this bond.

Owner earnings ¥502.5B on 1810M diluted shares; net debt ¥284.3B. The base opens on the through-cycle figure (the latest year sits above the record’s own median, and Graham’s averaging cuts both ways); clear Normalize to use the year as filed. Net of stock comp treats option pay as the expense it is. The dials set the multiple a growth belief justifies; the price, and every dollar on this page, is yours.

Figures from EDINET, the Financial Services Agency’s disclosure system, the same kind of filing the US pages draw from EDGAR. A separate pool: these names never pass through the US industry classifier.

Manual order: ← 4502 its page in the Manual 4506 →

Industry order: ← 4502 the Pharmaceuticals chapter 4506 →